Clinical trials: Pneumococcal Conjugate Vaccine
Pneumococcal Infections
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
The 13-valent pneumococcal conjugate vaccine (13vPnC) is being developed for adults to prevent pneumococcal diseases such as meningitis (inflammation of the brain lining), septicemia (blood poisoning), and pneumonia (inflammation…
- Trial name
- NCT00492557
- Testing
- 13-valent pneumococcal conjugate vaccine, 13vPnC + TIV
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Pfizer
13-valent Pneumococcal Vaccine, Premature Birth
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
The purpose of this study is to describe the safety, tolerability, and immunogenicity of a 2,3,4 and 12 month schedule of the 13-valent pneumococcal conjugate vaccine when given to preterm infants with concomitant vaccines…
- Conditions
- 13-valent Pneumococcal Vaccine, Premature Birth, Immunization, Safety
- Trial name
- NCT01193335
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 12 sites in Poland, Spain
- Volunteers
- 200 people
- Sponsor
- Pfizer
Pneumococcal Infectious Diseases
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).
- Trial name
- NCT07593924
- Testing
- Sinovac PCV13, Prevenar 13™
- Where
- Philippines
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Invasive Pneumococcal Disease
Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.
The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
- Trial name
- NCT00227188
- Testing
- Pneumococcal 7-valent conjugate vaccine Prevnar
- Where
- Spain
- Volunteers
- 408 people
- Sponsor
- Pfizer
Infections, Rotavirus
Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA
The aim of this this study is to confirm absence of immune interference between HRV vaccine and routine infant vaccinations currently in use in the USA.
- Trial name
- NCT00334607
- Testing
- 2-dose oral live attenuated G1P[8] human rotavirus vaccine
- Where
- 42 sites in United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.
- Trial name
- NCT05667740
- Testing
- Gamma-PN3, Prevenar-13, Pneumovax-23
- Where
- Australia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Pneumococcal Pneumonia, Pneumonia, Bacterial
Phase I to Test a New Pneumococcal Vaccine
To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers.
- Trial name
- NCT03303976
- Testing
- Bioconjugate pneumococcal vaccine, Multivalent plain polysaccharide vaccine
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
The purpose of this study will be to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants given with routine pediatric vaccinations in Canada.
- Trial name
- NCT00475033
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7-valent pneumococcal conjugate vaccine
- Where
- 11 sites in Canada
- Volunteers
- 603 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
The aim of the current study is to determine whether ibuprofen, given as immediate or delayed prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune response in children receiving primary…
- Trial name
- NCT01235949
- Testing
- GSK1024850A (SynflorixTM), Infanrix hexa, Infanrix-IPV/Hib
- Where
- 23 sites in Romania
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
The purpose of this observer blind study is to assess the safety in terms of fever >39°C (rectal temperature) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK…
- Trial name
- NCT00547248
- Testing
- Synflorix, Tritanrix-HepB, Hiberix
- Where
- 7 sites in Philippines, Poland
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Immunization, Safety
A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market.
- Trial name
- NCT06760208
- Testing
- Pneumococcal 20-valent conjugate vaccine
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Meningitis
Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar.
- Trial name
- NCT00227214
- Where
- 39 sites in Spain
- Volunteers
- 160 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Immunisation, Diphtheria Immunisation
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Primary objectives: To assess the safety profile of each SP0202 formulation and Prevnar 13 in toddlers and infants (after each and any injection).
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation
- Trial name
- NCT04398706
- Testing
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3
- Where
- 57 sites in United States, Canada and 2 more
- Volunteers
- 852 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company